false 0000882361 0000882361 2025-01-14 2025-01-14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

January 14, 2025

(Date of Report - date of earliest event reported)

 

 

Aptose Biosciences Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

 

 

Canada   001-32001   98-1136802

(State or Other Jurisdiction of

Incorporation or Organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

66 Wellington Street West, Suite 5300

TD Bank Tower, Box 48

Toronto, Ontario M5K 1E6

Canada

(Address of Principal Executive Offices)

(647) 479-9828

(Registrant’s Telephone Number, Including Area Code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Shares, no par value   APTO   The Nasdaq Stock Market

 

 

 

Item 3.01.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On January 14, 2025, Aptose Biosciences Inc. (the “Company”) received an additional staff determination letter (the “Letter”) from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last thirty (30) consecutive business days, the closing bid price for the Company’s common shares have been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Company is required to present its plan of compliance to the hearings panel. The Company’s common shares continue to trade on the Toronto Stock Exchange (“TSX”) under the symbol “APS”. The Company’s listing on the TSX is independent and will not be affected by the Nasdaq listing status.

The Company has been given until March 31, 2025, to regain compliance with the Minimum Bid Price Requirement. The Company will hold a Special Shareholders’ meeting next Monday, January 27, 2025 to ask shareholders to approve a reverse stock split which is aimed to increase the Company’s stock price.

The Company intends to monitor the closing bid price of its common shares and may, if appropriate, consider available options to regain compliance with the Minimum Bid Price Requirement. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq Listing Rules.

 

Item 9.01.

Financial Statements and Exhibits

 

Exhibit
No.		    Description of Exhibit
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 21, 2025

 

APTOSE BIOSCIENCES INC.
By:  

/s/ Fletcher Payne

Name:   Fletcher Payne
Title:   Senior Vice President and Chief Financial Officer
v3.24.4
Document and Entity Information
Jan. 14, 2025
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0000882361
Document Type 8-K
Document Period End Date Jan. 14, 2025
Entity Registrant Name Aptose Biosciences Inc.
Entity Incorporation State Country Code Z4
Entity File Number 001-32001
Entity Tax Identification Number 98-1136802
Entity Address, Address Line One 66 Wellington Street West, Suite 5300
Entity Address, Address Line Two TD Bank Tower
Entity Address, Address Line Three Box 48
Entity Address, City or Town Toronto
Entity Address, State or Province ON
Entity Address, Postal Zip Code M5K 1E6
Entity Address, Country CA
City Area Code (647)
Local Phone Number 479-9828
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Security 12b Title Common Shares, no par value
Trading Symbol APTO
Security Exchange Name NASDAQ
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Aptose Biosciences Charts.
Aptose Biosciences (NASDAQ:APTO)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Aptose Biosciences Charts.